• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制性 CpG 序列可减少小鼠模型中缺血/再灌注引起的肝肿瘤肝转移。

Inhibitory CpG sequences reduced ischemia/reperfusion-induced hepatic metastases of liver tumor in a murine model.

机构信息

Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing, China.

出版信息

J Surg Res. 2012 Nov;178(1):248-54. doi: 10.1016/j.jss.2012.01.057. Epub 2012 Apr 1.

DOI:10.1016/j.jss.2012.01.057
PMID:22502906
Abstract

BACKGROUND

It is reported that hepatic ischemia/reperfusion (I/R) during hepatectomy accelerates liver tumor growth. Hepatic I/R induces inflammation cytokines, which can accelerate the outgrowth of liver tumor. Inhibitory CpG sequence (iCpG) is an inhibitor of TLR9, which plays an important role in hepatic I/R. The aim of this study was to examine whether iCpG could prevent hepatic I/R-induced metastases of the liver tumor.

MATERIALS AND METHODS

A murine tumor model that underwent partial hepatic I/R or sham operation was treated with iCpG or control DNA sequence (Ctrl ODN). Tumor growth and metastases were observed on day 14 after surgery; Endothelial leukocyte adhesion molecules such as E-selectin and intracellular adhesion molecule-1 (ICAM-1) protein expression were measured 24 h after reperfusion by Western blotting; E-selectin and ICAM-1 mRNA expression in hepatic tissue was measured 2 h after reperfusion by RT-PCR; NF-κB activity in hepatic tissue was measured 2 h after reperfusion by electrophoretic gel mobility shift assay.

RESULTS

The tumor growth in the mice subjected to hepatic I/R was remarkably stimulated when compared with the mice subjected to laparotomy alone. The iCpG had no significant inhibitory effect on tumor growth in sham-operated mice subjected to tumor. However, iCpG could reduce the tumor growth and inhibit the activation of NF-κB and downregulate the E-selectin and ICAM-1 mRNA and protein in the mice with tumor subjected to I/R.

CONCLUSIONS

ICpG might reduce I/R-induced hepatic metastases of liver tumor cells by inhibiting NF-κB expression and downregulating the adhesive molecules, such as E-selectin and ICAM-1.

摘要

背景

据报道,肝切除术中的肝缺血/再灌注(I/R)会加速肝肿瘤生长。肝 I/R 诱导炎症细胞因子,从而加速肝肿瘤的生长。抑制性 CpG 序列(iCpG)是 TLR9 的抑制剂,在肝 I/R 中发挥重要作用。本研究旨在探讨 iCpG 是否可以预防肝 I/R 引起的肝肿瘤转移。

材料与方法

建立部分肝 I/R 或假手术的小鼠肿瘤模型,并用 iCpG 或对照 DNA 序列(Ctrl ODN)处理。术后第 14 天观察肿瘤生长和转移;再灌注后 24 小时通过 Western blot 测定内皮白细胞黏附分子如 E-选择素和细胞间黏附分子-1(ICAM-1)蛋白表达;再灌注后 2 小时通过 RT-PCR 测定肝组织中 E-选择素和 ICAM-1mRNA 表达;再灌注后 2 小时通过电泳凝胶迁移率变动分析测定肝组织中 NF-κB 活性。

结果

与单独剖腹手术相比,肝 I/R 小鼠的肿瘤生长明显受到刺激。iCpG 对假手术的荷瘤小鼠的肿瘤生长没有明显的抑制作用。然而,iCpG 可以减少 I/R 荷瘤小鼠的肿瘤生长,抑制 NF-κB 的激活,并下调 E-选择素和 ICAM-1mRNA 和蛋白的表达。

结论

iCpG 可能通过抑制 NF-κB 表达和下调黏附分子如 E-选择素和 ICAM-1,减少 I/R 引起的肝肿瘤细胞肝转移。

相似文献

1
Inhibitory CpG sequences reduced ischemia/reperfusion-induced hepatic metastases of liver tumor in a murine model.抑制性 CpG 序列可减少小鼠模型中缺血/再灌注引起的肝肿瘤肝转移。
J Surg Res. 2012 Nov;178(1):248-54. doi: 10.1016/j.jss.2012.01.057. Epub 2012 Apr 1.
2
Induction of E-selectin after partial hepatectomy promotes metastases to liver in mice.部分肝切除术后E-选择素的诱导促进小鼠肝脏转移。
J Surg Res. 2001 Apr;96(2):197-203. doi: 10.1006/jsre.2001.6095.
3
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.阿托伐他汀通过 Toll 样受体 4 抑制和内皮型一氧化氮合酶激活来保护肥胖小鼠免受肝缺血再灌注损伤。
J Gastroenterol Hepatol. 2012 Aug;27(8):1353-61. doi: 10.1111/j.1440-1746.2012.07123.x.
4
Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases--activation of cell invasion and migration pathways.小肝残余缺血再灌注促进肝肿瘤生长和转移——细胞侵袭和迁移途径的激活
Liver Transpl. 2007 Dec;13(12):1669-77. doi: 10.1002/lt.21193.
5
Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation.尿胰蛋白酶抑制剂通过减少核因子-κB激活来减轻肝脏缺血再灌注损伤。
Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):53-8.
6
The effect of intraportal prostaglandin E1 on adhesion molecule expression, inflammatory modulator function, and histology in canine hepatic ischemia/reperfusion injury.门静脉内注射前列腺素E1对犬肝缺血/再灌注损伤中黏附分子表达、炎症调节因子功能及组织学的影响
J Surg Res. 2007 Mar;138(1):88-99. doi: 10.1016/j.jss.2006.05.009. Epub 2006 Dec 15.
7
The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice.不同剂量的TLR9拮抗剂iCpG-ODN可抑制小鼠脑缺血/再灌注损伤。
CNS Neurol Disord Drug Targets. 2017;16(5):624-633. doi: 10.2174/1871527316666170206150259.
8
Protective effect of pyrrolidine dithiocarbamate on liver injury induced by intestinal ischemia-reperfusion in rats.吡咯烷二硫代氨基甲酸盐对大鼠肠缺血再灌注所致肝损伤的保护作用
Hepatobiliary Pancreat Dis Int. 2006 Feb;5(1):90-5.
9
Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway.内源性危险信号通过Toll样受体4/核因子-κB途径引发肝脏缺血/再灌注损伤。
Chin Med J (Engl). 2007 Mar 20;120(6):509-14.
10
Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion.蛋白酶体抑制剂乳胞素可消除肠道缺血再灌注诱导的肝损伤。
Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1102-8. doi: 10.1111/j.1440-1681.2007.04674.x.

引用本文的文献

1
Surgical stress and cancer progression: the twisted tango.手术应激与癌症进展:扭曲的探戈。
Mol Cancer. 2019 Sep 2;18(1):132. doi: 10.1186/s12943-019-1058-3.
2
Adverse impact of intermittent portal clamping on long-term postoperative outcomes in hepatocellular carcinoma.间歇性门静脉阻断对肝细胞癌术后长期预后的不良影响。
Ann R Coll Surg Engl. 2017 Jan;99(1):22-27. doi: 10.1308/rcsann.2016.0183. Epub 2016 Jun 6.
3
Impact of intermittent portal clamping on the early recurrence of hepatocellular carcinoma after surgery.间歇性门静脉阻断对肝癌术后早期复发的影响
Surg Today. 2016 Nov;46(11):1290-5. doi: 10.1007/s00595-016-1316-6. Epub 2016 Mar 2.
4
TLR9 is dispensable for intestinal ischemia/reperfusion-induced tissue damage.Toll样受体9对于肠道缺血/再灌注诱导的组织损伤并非必需。
Am J Clin Exp Immunol. 2012;1(2):124-135.